摘要
目的:化疗是控制癌症发展。延长患者生命的重要治疗方法,但化疗相关腹泻是很多化疗方案的不良反应,常带给癌症患者痛苦且导致营养不良及体液、蛋白质和电解质的减少,严重可致化疗过程中断,严重影响化疗进程,并且增加住院费用,加重患者心理负担,降低肿瘤的治疗效果,其发病机制尚不清楚,目前无统一的治疗方案,本文探讨醋酸奥曲肽治疗严重化疗相关性腹泻的疗效。方法:将2006年1月～2008年6月本科严重化疗相关性腹泻患者62例,随机分为治疗组和对照组,治疗组采用醋酸奥曲肽注射液(力尔宁,Li Er Ning Injection,简称LEN)0.15～0.2mg+0.9%氯化钠注射液50mL内,8h静脉持续泵入或静脉滴注,对照组给予思密达治疗。观察患者治疗前后的KPS评分和腹泻的治疗效果并进行统计学分析。结果:治疗组腹泻治愈总有效率93.7%,对照组为40%,P<0.05。治疗前治疗组与对照组KPS评分无显著性差异;治疗组治疗后KPS评分较治疗前明显增高,有显著性差异;治疗后治疗组KPS评分明显高于对照组;对照组治疗前后则无显著性差异。结论:利尔宁(醋酸奥曲肽注射液)为吉林一心制药有限公司的产品,在本研究中证实醋酸奥曲肽注射液8h持续静脉泵入或静脉滴注可以治疗严重的化疗相关性腹泻(CID),可减轻患者痛苦,保证化疗顺利进行。醋酸奥曲肽对严重化疗相关性腹泻疗效好,不良反应少,改善患者的生存质量,值得在临床中进一步推广。
Objective： Chemotherapy is an important treatment in controlling the development of cancer and extending the life of patients, but chemotherapy-related diarrhea is an adverse effect in many chemotherapeutic regimens that results in pain, malnutrition and reduction of body fluids, proteins and electrolytes. Chemotherapy-induced diarrhea （CID） often severely affects the chemotherapy process, increases hospital cost and exacerbates patients＇ psychological burden. The purpose of this study was to summarize the therapeutic effect of Octreotide acetate on chemotherapy-induced diarrhea. Methods： A total of 62 cases of severe chemotherapy-induced diarrhea seen in our department between January 2006 and June 2008 were divided into the Octreotide acetate group （32） and the control group （30）. Li Er Ning （LIEN） injections （0.15-0.2mg＋NS 50ml, 8h iv） were administered in the Octreotide acetate group. Patients in the control group received Smecta. The Karnofsky performance status （KPS） score was recorded and the therapeutic outcome was observed. Results： The total effective rate in the Octreotide acetate group was 93.7% compared with 40% in the control group （P〈 0.05）. No significant difference was found in pre-treatment KPS score between the Octreotide acetate group and the control group. For the Octreotide acetate group, KPS score after treatment was significantly higher than that before treatment. Post-treatment KPS score in the Octreotide acetate group was significantly higher than that in the control group. For the control group, no significant difference was found in KPS scores before and after treatment. Conclusion： Intravenous injection of Octreotide acetate is effective for CID, reducing pain and ensuring the smooth progress of chemotherapy. Octreotide acetate has few adverse reactions and can improve the quality of life for patients with CID.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2009年第12期669-671,共3页
Chinese Journal of Clinical Oncology
